Elizabeth Cairns is a Senior writer at Scrip. She specializes in medicine and healthcare, with a focus on topics such as healthcare technology, alternative medicine, and wellness, while also covering markets and biotech developments. Elizabeth's work has been featured in Informa, Citeline, and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Elizabeth Cairns' coverage primarily focuses on the healthcare and pharmaceutical industry, with a strong emphasis on biopharmaceuticals, clinical trials, drug development, and medical research. She frequently cites data and press releases in her articles.
If you are looking to reach out to Elizabeth Cairns for potential coverage or collaboration opportunities, consider offering access to exclusive data or insights related to breakthroughs in drug development or clinical trial results. Given her focus on scientific themes as well as private sector announcements, she might be interested in pitches that provide unique perspectives from key figures within pharmaceutical companies regarding new developments and trends shaping the industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Elizabeth Cairns
Nippon Shinyaku has paid $110 million upfront for the rights to sell two of Regenxbio's gene therapies for mucopolysaccharidosis in the US and Asia. …
By: Elizabeth Cairns
AstraZeneca's Calquence became the first BTK inhibitor approved in the US for first-line use in mantle cell lymphoma on Thursday. The drug
By: Elizabeth Cairns
Following the poorer-than-hoped performance of CagriSema last month , Novo Nordisk needed an emphatic clinical success with its high-dose version of Wegovy. The …
By: Elizabeth Cairns
Study links GLP-1 diabetes drugs like Novo's Ozempic and Eli Lilly's Mounjaro to 12% lower Alzheimer's risk, ahead of Novo's Phase 3 semaglutide Alzheimer's trials.
By: Elizabeth Cairns
Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in major/clinically relevant bleeds at 150mg dose
By: Elizabeth Cairns
Novo Nordisk's subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical trial, the Danish company …
This year has already started strong for obesity drug developers, with Novo Nordisk, Metsera and Hengrui/Kailera all proclaiming clinical successes for GLP-1-based drugs. What might …
By: Elizabeth Cairns
Akero Therapeutics claimed a win in severe MASH on Monday morning , as the company's candidate efruxifermin showed a 24% benefit on …
By: Elizabeth Cairns
ITM Isotope Technologies Munich plans to seek approval for its β-emitting radioligand in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) following a Phase 3 success, the biotech said …
By: Elizabeth Cairns
Roche's M&A strategy in the coming year revolves around derisked mechanisms and high unmet needs, CEO Thomas Schinecker said Thursday. And further dealmaking over assets …
(833) 317-6278 
